ISSN: 2643-5713
Annals of Lung Cancer is an international, open access, peer reviewed journal focusing to publish various types, stages, causes, signs and symptoms, diagnosis, prognosis and survival rate, treatment and management of Lung Cancers. This journal brings novel insights concerning all the clinical, experimental, translational and basic science of malignancies of the lung and chest region. All the published content in the journal are freely accessible without any restriction under Creative Commons Attribution License.
The journal invites various article formats such as original, reviews, cases, clinical images, communications and other short article types providing in depth information related but not limited to prevention, epidemiology and etiopathology, basic biology, cytopathology, clinical assessment, surgery, chemotherapy, radiotherapy, possible treatment modalities, possible biomarkers for early detection, other treatment modalities and survivals of lung cancer.
The journal publishes only selective articles after thorough peer review processing of the manuscripts by international research experts.
Medical Director
Telepathology and Clinical Laboratory Medicine
Grafton City Hospital
United States of America
Professor
Medical Oncology Department
Universidad Catolica de Valencia San Vicente Martir.
Valencia, Spain
Tel: +34-961265877
Professor
Internal Medicine and Surgery
University of Catania
Italy
Tel: +390953781573
Associate Professor
Division of Biostatistics
University of North Texas
United States of America
Tel: 215-776-9458
Associate Professor
Tissue and Cell Biology Department
Medical School of UNAM
United States of America
Tel: 52-55-56-23-21-83
Associate Professor
College of Pharmacy
Keimyung University
South Korea
Tel: 053-580-6639
Submit your manuscript to this journal through online or email us at editorialoffice@scholars.direct
Research Article
In comparison with the median, the restricted mean survival time (RMST) has a specific advantage because it examines the whole survival curve (like th... Read more
Case Report
Endobronchial Sarcoma: A Case Report and Review of Literature
Pulmonary sarcomatoid carcinomas (PSCs) are poorly differentiated non-small cell lung carcinomas (NSCLCs) that, loosely, consist of a sarcoma-like ele... Read more
Review Article
Patients with Oligometastatic (OM) non-small-cell lung cancer (NSCLC) (≤ 3 metastases) might benefit from radical ablative treatment of both primary... Read more
Research Article
Determination of intrafraction motion in stereotactic body radiation therapy (SBRT) of non-small-cell lung cancer (NSCLC) usually involves generating... Read more
Research Article
Impact of an Onsite Endobronchial Ultrasound Program on the Time to Treatment of Cancer in Veterans
Endobronchial ultrasound (EBUS) is commonly employed in the diagnostic evaluation of pulmonary nodules and for mediastinal staging of lung cancer. We ... Read more
Editorial
All participants understand that the information will be published anonymously, but that full anonymity cannot be guaranteed. We understand that the t... Read more
Original Research
Lobaplatin or Cisplatin Plus Etoposide for Treating Extensive Stage Small Cell Lung Cancer
The EL and EP groups did not differ substantial in objective response rate, hospital stay, or rate of leukocyte and platelet decrease. In the two grou... Read more
Original Research Article
Longitudinal inception cohort study (1974-2004) on miners who started working underground at two coal mines in Germany between 1974 and 1979. From the... Read more
Original Article
Comprehensive dust control and health protection measures have been implemented to prevent coal workers' pneumoconiosis (CWP) in German collieries sin... Read more
Research Article
Survival and Grades vs. Costs and Values of Nivolumab in Cancer; the Impact of PD-L1 Positivity
Nivolumab (Nivo) is a programmed death receptor-1 immune check point antibody widely used in cancer.... Read more
